. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol. 2016 May 1;73(5):561-71. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)
Cohort
(N)
Measurement
Mean ± SD
Method;
Assay Name;
Manufacturer
Diagnostic
Criteria
Aβ42
(CSF)
AD
(95)
390 ± 18†
pg/mL
ELISA;
Innotest;
Innogenetics
Albert et al., 2011
Aβ42
(CSF)
CTRL-
Other Controls
(207)
613 ± 18†
pg/mL
ELISA;
Innotest;
Innogenetics
VLP-1
(CSF)
AD
(95)
514 ± 17†
pg/mL
Single Molecule Counting Immunoassay;
Erenna;
Singulex, Inc.
Albert et al., 2011
VLP-1
(CSF)
CTRL-
Other Controls
(207)
397 ± 10†
pg/mL
Single Molecule Counting Immunoassay;
Erenna;
Singulex, Inc.
neurogranin
(CSF)
AD
(95)
2.02 ± 0.1†
ng/mL
Single Molecule Counting Immunoassay;
Erenna;
Singulex, Inc.
Albert et al., 2011
neurogranin
(CSF)
CTRL-
Other Controls
(207)
1.47 ± 0.06†
ng/mL
Single Molecule Counting Immunoassay;
Erenna;
Singulex, Inc.
tau-total
(CSF)
AD
(95)
602 ± 29†
pg/mL
ELISA;
Innotest;
Innogenetics
Albert et al., 2011
tau-total
(CSF)
CTRL-
Other Controls
(207)
296 ± 11†
pg/mL
ELISA;
Innotest;
Innogenetics

† Mean ± SEM

Recommends

Please login to recommend the paper.

Comments

  1. I definitely think this study strengthens the case for CSF neurogranin (Ng) as an AD biomarker. I think the expression of Ng in synapses, in conjunction with the increase in AD CSF, suggests that it may be a marker of synaptic degeneration in AD. I believe synapses are more dynamic than axons and neuronal bodies so perhaps this will be a fast marker to normalize in response to successful treatment, a marker faster than t-tau and/or p-tau. Although the study does not add much entirely novel information, it is a completely independent confirmation of patterns already seen by other research groups; such confirmation is essential in biomarker research.

  2. I'd like to thank Dr. Zetterberg for his comment, and agree with it overall. However, this paper does contain novel information regarding the value of neurogranin as a preclinical biomarker for AD, and its ability to predict future cognitive impairment in cognitively normal individuals, which had not previously been investigated. Also, the question with most new biomarkers is whether they add any additional information to standard biomarkers. On this, we were able to show that despite the strong correlation between neurogranin and tau/p-tau181 levels, the addition of neurogranin to combinations of other biomarkers (tau, p-tau181, Aβ42, and VILIP-1) provides additional information to any of these combinations, and significantly complements their predictive ability for future cognitive decline. Our published data represents work that was started several years ago, prior to any published work about neurogranin. I agree with Dr. Zetterberg's comments regarding the value of synaptic markers as dynamic indicators.

Make a Comment

To make a comment you must login or register.